(22267) A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease and type 1 diabetes

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-503024-27-00

Acronym

22267

Enrollment

105

Registered

2023-10-12

Start date

2024-02-27

Completion date

2025-09-15

Last updated

2025-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease associated with type 1 diabetes mellitus

Brief summary

Change in UACR from baseline (ratio to baseline) over 6 months

Detailed description

Number of participants with TEAEs, TESAEs and Hyperkalaemia (AESI)

Interventions

DRUGFinerenone

DRUGBAY 94-8862

DRUGplacebo equal to test product except active substance

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in UACR from baseline (ratio to baseline) over 6 months	—

Secondary

Measure	Time frame
Number of participants with TEAEs, TESAEs and Hyperkalaemia (AESI)	—

Countries

Denmark, Germany, Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026